台灣臨床試驗主持人資料庫|TPIDB

2016-07-01 - 2020-12-31

Others

Completed

A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARBOPLATIN PLUS ETOPOSIDE WITH OR WITHOUT ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) IN PATIENTS WITH UNTREATED EXTENSIVE-STAGE SMALL CELL LUNG CANCER

Condition/Disease

SMALL CELL LUNG CANCER
Test Drug

ATEZOLIZUMAB

Participate Sites
3Sites

Terminated3Sites

邱昭華

Taipei Veterans General Hospital

Division of Hematology & Oncology

楊政達

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2018-06-01 - 2023-03-21

Phase III

Completed

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of Gantenerumab in Patients With Early (Prodromal to Mild) Alzheimer's Disease

Condition/Disease

Alzheimer Disease
Test Drug

GANTENERUMAB

Participate Sites
8Sites

Terminated6Sites

劉景寬

Kaohsiung Municipal Gangshan Hospital

未分科

黃錦章

Linkou Chang Gung Medical Foundation

Division of Neurology

2018-07-01 - 2023-06-02

Phase III

Completed

A PHASE III, RANDOMIZED, MULTICENTER, OPEN-LABEL, TWO-ARM STUDY TO EVALUATE THE PHARMACOKINETICS, EFFICACY, AND SAFETY OF SUBCUTANEOUS ADMINISTRATION OF THE FIXED-DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER

Condition/Disease

HER2-POSITIVE EARLY BREAST CANCER
Test Drug

Pertuzumab and Trastuzumab FDC, Perjeta, Herceptin, Cyclophosphamide, Paclitaxel, Docetaxel, Doxorubincin

Participate Sites
4Sites

Terminated3Sites

曾令民

Taipei Veterans General Hospital

Division of General Surgery

陳訓徹

Linkou Chang Gung Medical Foundation

2016-03-01 - 2023-10-31

Phase III

Active

A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo and to Adalimumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Background of Methotrexate (MTX) and Who Have an Inadequate Response to MTX (MTX-IR)

Condition/Disease

Moderately to Severely Active Rheumatoid Arthritis
Test Drug

ABT-494

Participate Sites
10Sites

Terminated8Sites

賴建志

Taipei Veterans General Hospital

Division of Rheumatology

郭昶甫

Linkou Chang Gung Medical Foundation

Division of Rheumatology

2017-08-15 - 2023-11-30

Phase III

Completed

A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) - SELECT - PsA 1

Condition/Disease

Active Psoriatic Arthritis
Test Drug

ABT-494

Participate Sites
7Sites

Terminated6Sites

賴建志

Taipei Veterans General Hospital

Division of Rheumatology

郭昶甫

Linkou Chang Gung Medical Foundation

Division of Rheumatology

2017-11-01 - 2021-05-20

Phase III

Completed

A Randomized, Open-label, Multi-center Phase 3 study to Compare the efficacy and Safety of BGB-A317 versus Sorafenib as First-Line Treatment in patients with Unresectable Hepatocellular Carcinoma

Condition/Disease

unresectable HCC
Test Drug

Tislelizumab

Participate Sites
11Sites

Terminated9Sites

趙毅

Taipei Veterans General Hospital

Division of Hematology & Oncology

2016-05-01 - 2020-12-31

Phase II

Completed

Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo plus Cisplatin and Gemcitabine as First-Line Treatment in Patients with Advanced or Metastatic Biliary Tract Cancer.

Condition/Disease

Biliary Tract Cancer
Test Drug

Merestinib and Ramucirumab

Participate Sites
6Sites

Terminated5Sites

白禮源

China Medical University Hospital-Taipei

未分科

陳仁熙

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2017-09-01 - 2023-04-30

Phase III

Condition/Disease
Test Drug

Participate Sites
3Sites

Terminated3Sites

曾令民

Taipei Veterans General Hospital

Division of General Surgery

陳訓徹

Linkou Chang Gung Medical Foundation

Division of General Surgery

2015-07-01 - 2020-12-31

Phase II

Multicenter, open-label, single arm, Phase II study in advanced non-small cell lung cancer；Subtitle:A multicenter, open-label, single arm Phase II study to evaluate safety and efficacy of ONO-4538 in stage IIIB/IV or recurrent non-small cell lung cancer patients who are unsuited to radical radiotherapy and resistant to a platinum-base chemotherapeutic regimen.

Condition/Disease

stage IIIB/IV or recurrent non-small cell lung cancer
Test Drug

Opdivo®

Participate Sites
10Sites

Not yet recruiting1Sites

Terminated8Sites

陳育民

Taipei Veterans General Hospital

Division of Thoracic Medicine

楊政達

Linkou Chang Gung Medical Foundation

Division of Thoracic Medicine

2017-02-01 - 2019-04-30

Phase III

A Phase III Multi-Center, Double-Blind, Randomized, Parallel Group, Placebo-Controlled Clinical Trial in High-Risk Type 2 Diabetes Mellitus (T2DM) Subjects With Coronary Artery Disease (CAD) to Determine Whether Bromodomain Extraterminal Domain (BET) Inhibition Treatment With RVX000222 Increases the Time to Major Adverse Cardiovascular Events (MACE)

Condition/Disease

High-Risk Type 2 Diabetes Mellitus (T2DM) Subjects With Coronary Artery Disease (CAD)
Test Drug

RVX000222

Participate Sites
14Sites

Terminated14Sites

江晨恩

Taipei Veterans General Hospital

謝宜璋

Linkou Chang Gung Medical Foundation

Division of Cardiovascular Diseases

Search Result

List